Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613147 | 0.88 | HTT (0.53) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL263618 | 0.88 | HTT (0.53) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL7768580 | 0.86 | HTT (0.51) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL3629999 | 0.85 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL25221322 | 0.82 | HTT (0.46) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL7770663 | 0.81 | HTT (0.48) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL10615517 | 0.81 | BTN3A1 (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL29510856 | 0.81 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL1027272 | 0.81 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL719618 | 0.81 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4647434-A1 | MODULATOR FOR PROMOTING BINDING OF BUTYROPHILIN 3A1/2A1 | Unicet Biotech Co., LLC (CN) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024146627-A1 | MODULATOR FOR PROMOTING BINDING OF BUTYROPHILIN 3A1/2A1 | 北京清辉联诺生物科技有限责任公司 | 2024-07-11 | — | — | WO | disclosed |
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| CN-117402189-A | Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds | 广东集宝医药技术有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111848579-B | Prodrugs of 4- (2, 6-dichlorobenzoylamino) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 君实润佳(上海)医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111836818-B | Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds | 纽科利制药公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2014-02-27 | — | — | US | disclosed |
| EP-2681227-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana Biomed Limited (GB) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117246-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LIMITED (GB) | 2012-09-07 | — | — | WO | disclosed |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 2011-07-28 | — | — | US | disclosed |
| US-7879815-B2 | inhibitors of viral polymerases such as 5'-O-[[4-chloro-5-methyl-2-(1-methylethyl)phenoxy][[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phosphinyl]-2'-C-methylcytidine, used for the treatment of hepatitis C virus infection in mammals | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| EP-2274311-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100234316-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| WO-2009142827-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1987050-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | Merck & Co., Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007095269-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | HTT 4001/4885ALDH1A1 2409/4885KDM4E 3452/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | HTT 4012/4885ALDH1A1 2369/4885KDM4E 3419/4885 |
| US-20100234316-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection | NSUN2, NSUN3, RNGTT | HTT 3462/4885ALDH1A1 900/4885KDM4E 2007/4885 |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | TPMT, TYMP, MTAP | HTT 4287/4885ALDH1A1 877/4885KDM4E 1894/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | HTT 4598/4885ALDH1A1 3172/4885KDM4E 1084/4885 |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | HTT 4017/4885ALDH1A1 2381/4885KDM4E 3371/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | HTT 3959/4885ALDH1A1 2432/4885KDM4E 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.